Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24058293 | 0.88 | RIPK1 (0.35) | RIPK1ACVRL1 | |
| SCHEMBL23813354 | 0.88 | RIPK1 (0.35) | RIPK1ACVRL1 | |
| SCHEMBL21283687 | 0.84 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL18214622 | 0.82 | ACVRL1 (0.34) | RIPK1ACVRL1 | |
| SCHEMBL27284295 | 0.76 | RIPK1 (0.34) | RIPK1ACVRL1 | |
| SCHEMBL19223085 | 0.76 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL20959998 | 0.75 | RIPK1 (0.33) | RIPK1ACVRL1 | |
| SCHEMBL13532204 | 0.75 | ACVRL1 (0.34) | RIPK1ACVRL1 | |
| SCHEMBL15998209 | 0.75 | RIPK1 (0.35) | RIPK1ACVRL1 | |
| SCHEMBL22096275 | 0.74 | RIPK1 (0.32) | RIPK1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | RIPK1 902/4885ACVRL1 4649/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | RIPK1 902/4885ACVRL1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.